Pancreatic acinar cell carcinoma (PACC) occurs in the secretion glands of the pancreas. The rare disease accounts for only 0.5–1 percent of all pancreatic malignancies. A clinical trial led by Christine Campo Alewine, M.D. Ph.D., Lasker Clinical Research Scholar in the Laboratory of Molecular Biology, is now enrolling for PACC to test a drug that was approved previously by the Food and Drug Administration to treat similar cancers. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI Medical Oncology Referral Office at (240) 760-6050 or firstname.lastname@example.org
Clinicaltrials.gov identifier: NCT05286827
NCI Protocol ID: 000596
Official Title: Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.